Chemotherapy News and Research

Latest Chemotherapy News and Research

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

MicroRNA biomarker shows promise in predicting treatment response of ovarian cancer

Professor receives ALSF grant to develop cancer vaccine technology that help children to have healthy life

Professor receives ALSF grant to develop cancer vaccine technology that help children to have healthy life

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

Memorial Sloan-Kettering to use Sutro's cell-free protein synthesis technology to produce bispecific antibodies

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

Adenosine deaminase has potential to improve prognosis, diagnosis and treatment of ESCC

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

New approach aims to prevent brain cancer recurrence by attacking tumors at the source

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

Editing of protein-making sequences promotes development of ESCC, find NUS researchers

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

NICE issues Final Appraisal Determination for PIXUVRI (pixantrone) drug

Discovery opens new pathways for treatment of toxoplasmosis and malaria

Discovery opens new pathways for treatment of toxoplasmosis and malaria

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Study examines prevalence, severity and factors associated with chronic pain after breast cancer surgery

Study examines prevalence, severity and factors associated with chronic pain after breast cancer surgery

Innovative therapy offers new hope to breast cancer patients

Innovative therapy offers new hope to breast cancer patients

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

BBC TV report profiles NW Bio's DCVax-L Phase III trial for GBM brain cancer

Alliance for Cancer Gene Therapy grants nearly $25M to conduct cancer related gene therapy research

Alliance for Cancer Gene Therapy grants nearly $25M to conduct cancer related gene therapy research

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

FNIH Biomarkers Consortium announces initial results of I-SPY 2 trial for breast cancer

Researchers develop a class of compounds that may help eradicate Chagas disease

Researchers develop a class of compounds that may help eradicate Chagas disease

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

Scientists find inhibiting action of BRD4 protein may eradicate rare type of soft-tissue cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.